There is uncertainty about the development of airway tolerance to b-agonists and the phenomenon of rebound bronchoconstriction on b-agonist withdrawal. We have recently completed a study of the regular terbutaline and budesonide treatment in asthma. We report our observations on the eect of starting and stopping terbutaline treatment on morning and evening peak¯ows.
Introduction
Exposure of b-receptors to agonist leads to receptor downregulation in many tissues and tolerance to b-agonist eects (1) . The importance of downregulation of airway b-receptors during b 2 -agonist treatment in asthma is uncertain. Early reports indicated that signi®cant tolerance to their bronchodilator eects does not occur (2) . More recent studies have demonstrated a small reduction in the bronchodilator eect during treatment with long-acting b-agonist (3±5). Regular use of b-agonist has also been shown to lead to a reduction in functional antagonism to constricting stimuli (6) and a reduced bronchodilator response to b-agonist during acute bronchoconstriction (7) . Downregulation of airway b 2 -receptors may also explain the phenomenon of rebound bronchoconstriction on treatment withdrawal (8±10). Whether this withdrawal eect has clinical signi®cance is unclear, but in some circumstances it could conceivably contribute to an acute deterioration in asthma control in patients with brittle asthma.
We have recently reported a study of terbutaline and budesonide treatment designed to examine the interaction between these drugs (11) . The data obtained also allowed us to analyse the eects of starting and stopping terbutaline treatment. Our observations are reported here.
Methods
The study design has been reported elsewhere (11) . In brief, volunteers aged 9±64 with mild to moderate atopic asthma and bronchial hyperresponsiveness to methacholine (PC 20 8 mg ml 71 ) were recruited. Subjects on high dose inhaled corticosteroids (41500 mg day 71 in adults, 4800 mg day 71 in children aged513 years of age), oral steroids and current or ex-cigarette smokers (45 pack years) were excluded. The study was approved by the Otago Ethics Committee. Each subject (or their parent/guardian) gave written informed consent.
The study was a double-blind, random-order, doubledummy, cross-over comparison of four treatments: terbutaline 1000 mg four times daily, budesonide 400 mg twice daily, both drugs and placebo. Doses were halved for children under 13 years. Each treatment was given for 6 weeks. Inhaled corticosteroid treatment was withdrawn for at least 2 weeks before starting a 4 week single-blind placebo run-in during which no asthma treatment was used other than inhaled ipratropium bromide as required for symptom relief. Identical 4-week single blind washouts were used between each treatment. Subjects continued to use inhaled ipratorpium bromide for symptom relief throughout the study. No other asthma treatment was permitted except in the event of an exacerbation in which case the subject was withdrawn from the treatment period. Subjects kept a record of peak¯ows measured before the morning and evening doses of study inhalers. Spirometry and methacholine challenge tests were performed at the beginning and end of each treatment.
This analysis was a post hoc study of changes in morning and evening peak¯ow during terbutaline treatment. The mean changes in morning and evening peak¯ows were calculated for each day and each week of the treatment periods and washout intervals. The mean peak¯ows for the 2 weeks immediately prior to starting treatment, during which subjects were receiving single-blind placebo treatment, were used as the baseline for evaluating subsequent changes. Where data were available, the changes in peak ows on stopping treatment were also calculated. Unfortunately washout data were not collected following the last of the four treatment periods, hence these data are only available for approximately 75% of subjects. Changes from baseline on starting and stopping terbutaline were compared to the equivalent days on placebo using a one-way analysis of variance.
Results
Fifty-®ve subjects received terbutaline and 54 received placebo. One subject withdrew during terbutaline treatment because of tremor and had insucient data for analysis. Two subjects were excluded from analysis because of irregularities with their peak¯ow recording. Thus data were analysed for 52 subjects taking each treatment. The mean values for lung function data obtained during each treatment period are shown in the Table 1 .
Over the 6 weeks of regular treatment terbutaline did not signi®cantly alter mean morning peak¯ow with respect to either baseline or placebo [mean (95% CI) increase from baseline 2?5 (71?8, 6?8) l min
71
). However, analysis of the daily peak¯ow changes showed a mean (95% CI) increase 71 above baseline for the ®rst two mornings of terbutaline treatment followed by a return to baseline by day 3 (Fig. 1) . When compared to the corresponding days during placebo the mean peak¯ows were 25?0 and 17?3 l min 71 higher during terbutaline (P50?002 and P50?01, respectively).
On withdrawal of terbutaline there was a fall of 21?6 (4?1, 39?1) l min 71 below baseline on the ®rst morning after stopping treatment. This was signi®cantly lower than placebo [mean dierence between terbutaline and placebo of 23?1 l min 71 (P=0?024)]. Peak¯ows on the second morning after stopping terbutaline were not signi®cantly dierent from placebo and returned to baseline by day 3 (Fig. 1) .
Evening peak¯ows were signi®cantly higher during terbutaline treatment than during the baseline or placebo. (Fig. 2) .
After terbutaline was discontinued there was a small fall in evening peak¯ows below baseline [mean (95% CI) 8?3 l min 71 ]. This was not signi®cantly lower than the baseline but was of borderline signi®cance compared to placebo (mean dierence between placebo and terbutaline of 22?5 l min 71 , P=0?055) (Fig. 1) .
Discussion
The observations reported here were not based on an a priori hypothesis and require cautious interpretation. However, they strongly suggest the development of tolerance to the bronchodilator eect of terbutaline occurring within 2 days of starting treatment and that rebound bronchoconstriction occurred for a similar interval when terbutaline was withdrawn.
The increase in morning peak¯ows observed on starting terbutaline treatment was unexpected since morning peak ows were measured before the ®rst daily dose of terbutaline. However, this would be consistent with the evening doses having had a prolonged bronchodilator eect for the ®rst 2 days of treatment, followed by the development of tachyphylaxis to its duration of action by the third day. Shortening of the duration of the bronchodilator action of b-agonists has been described previously, although the time course for this eect has not (12±15).
FIG. 1.
Time trends in (a) morning and (b) evening peak¯ows before, during and after terbutaline treatment. Mean (+95% CI) changes from baseline are shown for each day of the weeks before (run-in) and after starting terbutaline, for the 6 weeks of the treatment period, and for each day of the weeks before and after stopping treatment. Mean changes of the placebo treatment period are indicated by the broken line. The baseline was de®ned as the mean peak¯ow of the last 2 weeks of each of the pre-treatment washouts.
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Evening peak¯ows were measured before the ®nal daily dose of study medication Ð typically 4±5 h after the afternoon dose. The ®nding that the increase in mean peak ow was greater for the ®rst two evenings of terbutaline than during the remainder of the treatment period suggests that this may also have been aected by tachyphylaxis. A similar eect was noted in a study of the long-acting b-agonist, formoterol, in which there was a reduced increase in peak¯ows after 2 days of treatment (16) . However, in that study, the use of a long-acting b-agonist meant that this eect was observed in morning peak¯ows which were measured after a longer (overnight) interval after administration of the previous dose.
The fall in mean peak¯ow below baseline on the ®rst morning after stopping terbutaline treatment suggests rebound bronchoconstriction. This is consistent with previous ®ndings (8±10). The eect was not caused by the methacholine challenge procedure at the clinic visit since it was not observed at the time of stopping placebo treatment. However, the use of salbutamol after the methacholine challenge may have masked a rebound fall in evening peak ow on the day of terbutaline withdrawal. Thus the mean evening peak¯ow did not fall signi®cantly below baseline on this day, but did appear to be reduced compared to placebo (P=0?055).
The timing of these changes is consistent with evidence that downregulation of b 2 -receptors on bronchial epithelial cells and alveolar macrophages occurs after 24 h of regular inhaled b-agonist treatment (17) . Our data suggest that spontaneous recovery of b 2 -receptor function in bronchial smooth muscle occurs over a similar period.
The eects of regular terbutaline on overall asthma control, spirometry, bronchial hyperresponsiveness to methacholine and morning peak¯ows in this study have previously been reported (11) . There was no evidence that terbutaline had an adverse eect on any of these outcomes over the 6 week study period (Table 1) . However, the observations reported here suggest that terbutaline treatment leads to signi®cant downregulation of airway breceptors. The clinical signi®cance is uncertain in view of the overall stability of asthma control during terbutaline. The magnitude of the mean peak¯ow changes reported here is not large (approximately 20 l min 71 ) and recovery of b-receptor function appears to be rapid. Despite this it is possible that loss of b-receptor function during regular bagonist treatment contributes to an acute deterioration in asthma control if treatment is stopped abruptly in some patients. We have demonstrated that patients may fail to respond adequately to bronchodilator as a result of regular b-agonist use (17) . A combination of these factors may partly explain the association between frequent use of bagonists with asthma mortality (18, 19) .
